Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent

ANGELO B. CEFALÙ1, GIACOMA BARRACO1, DAVIDE NOTO1, VINCENZA VALENTI1, CARLO M. BARBAGALLO1, GERARDO D. ELISIR3, LUIS A. CUNIBERTI4, JOSÉ P. WERBA5, MASSIMO LIBRA6, SALVATORE COSTA2, FABRIZIO GIANGUZZA2, ALBERTO NOTARBARTOLO1, SALVATORE TRAVALI6 and MAURIZIO R. AVERNA1

Departments of 1Internal Medicine and Geriatrics, 2Cellular and Development Biology, University of Palermo, Italy; 3Institute of Cardiology and Cardiovascular Surgery, 4Lipid and Atherosclerosis Research Laboratory, Department of Pathology, University Dr. Rene G. Favaloro, Favaloro Foundation, Buenos Aires, Argentina; 5Centro Cardiologico Monzino, IRCCS, Milan; 6Department of Biomedical Sciences, Section of Clinical Pathology and Molecular Oncology, University of Catania, Italy

Received October 5, 2005; Accepted November 18, 2005

Abstract. Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease caused by mutations in the gene coding for the low density lipoprotein receptor (LDL-R). It is characterized by a high concentration of low density lipoprotein (LDL), which frequently gives rise to premature coronary artery disease. We studied the probands of five FH Sicilian families with ‘definite’ FH and one proband of Paraguayan descent with homozygous FH who has been treated with an effective living-donor liver transplantation. In order to seek the molecular defect in these six families, we used direct sequencing to define the molecular defects of the LDL-R gene responsible for the disease. We described three novel missense mutations (C100Y, C183Y and G440C), two frameshift mutations (g.1162delC in exon 8 and g.2051delC in exon 14) and one mutation (g.2390-1G → A) at splicing acceptor consensus sequences located in intron 16 of the LDL-R gene; the analysis of cDNA of this splicing mutation showed the activation of a cryptic splice site in intron 16 and the binding studies showed a reduction in internalisation of LDL-DIL in the proband’s cultured fibroblasts. Moreover, a g.2051delC in exon 14 was identified in the proband of Paraguayan ancestry with clinical features of homozygous FH. The mutation identified in the South American patient represents the first description of a variant in South American patients other than Brazilian FH patients. The 5 mutations identified in the Sicilian patients confirm the heterogeneity of LDL-R gene mutations in Sicily.

Introduction

Familial hypercholesterolemia (FH; MIM #143890) is an autosomal dominant inherited disease caused by mutations in the gene coding for the low density lipoprotein receptor (LDL-R). LDL-R mediates the specific uptake and catabolism of LDL in the liver and many other tissues (1). Heterozygous carriers of a defective LDL-R gene express only half the number of functional receptors and have markedly raised plasma cholesterol levels that are frequently associated with tendon xanthomata, accelerated atherosclerosis, and premature coronary artery disease (2,3). Homozygous individuals are more severely affected and may die from coronary artery disease before reaching the age of maturity.

The prevalence of heterozygous FH appears to be ~0.2% in European and North American populations (4). Except for few populations in which founder mutations have been described, the defects underlying FH are very heterogeneous and each family is a priori expected to present a unique LDL-R mutation (5-7). So far, >900 different mutations of the LDL-R gene, largely being point mutations or small deletions and insertions, have been reported (8; http://www.ucl.ac.uk/fh; http://www.umd.necker.fr).

Currently, the diagnosis of FH is generally based on clinical presentation. However, the phenotype of the disease is variable, even among patients with the same genetic mutation, and clinical symptoms of the disease may not always be apparent, especially in young adults and children (9-11). Therefore, a specific molecular diagnosis is desirable in order to stratify the patient's individual risk.

Routinely, laboratory strategies for FH mutation analysis consist of Southern blot analysis and direct sequencing of the whole gene, including the promoter region, the 18 exons and their flanking intron regions. In the present report, we describe
the identification of six novel mutations in the LDL-R gene in five Sicilian families and in a family from Argentina.

Materials and methods

Subjects and pedigrees. The probands of five Sicilian FH families were referred to the Lipid Disorders Clinic at the University Hospital of Palermo for investigation. The diagnosis of 'definite' familial hypercholesterolemia was based on the criteria of the Simon Broom Register (9) and on the exclusion of secondary hypercholesterolemia causes.

The DNA from a proband of Paraguayan descent living in Argentina with clinically diagnosed homozygous FH was analysed in order to seek the molecular defect.

Informed consent was obtained from all subjects investigated. The study protocol was approved by the institutional human investigation committee of each participating institution. Pedigrees are shown in Fig. 1.
Family 1: the proband (III.1) was a 40-year-old Caucasian Sicilian male with severe hypercholesterolemia (total cholesterol = 9.04 mmol/l). On clinical examination no xanthelasmas or tendon xanthomas were present. Ultrasound examination revealed an increase of the carotid intima-media thickness (IMT). The proband reported that his mother suffered of hypercholesterolemia and coronary artery disease and died at the age of 42 years after coronary artery bypass surgery; moreover, an uncle (II.3) died at the age of 36 years of acute myocardial infarction. One of the sons (III.1), 21 years old, was tested afterwards and showed high plasma total cholesterol levels (8.9 mmol/l). The proband reported also that his mother was referred to the Lipid Clinic for hypercholesterolemia; the father (I.1) died of myocardial infarction. The proband's mother (I.2) had hypercholesterolemia, tendinous xanthomas and coronary artery disease; moreover, an uncle (II.5), and one niece (III.6) with hypercholesterolemia and his father (I.1) died of myocardial infarction.

Family 2: two brothers, 36 and 33 years old (I.II. and II.3), were referred to us with hypercholesterolemia (total cholesterol = 7.7 and 7.5 mmol/l, respectively). On clinical examination, no xanthelasmas or tendon xanthomas were present. Ultrasound examination of carotid arteries did not reveal significant alterations of the arterial wall. The 12-year-old daughter of proband II.I (III.2) also had hypercholesterolemia (9.7 mmol/l). Both the proband and her daughter did not have xanthelasmas or tendon xanthomas and ultrasound of carotid arteries did not document the presence of plaques. During the last year, II.4 has been treated with atorvastatin (10 mg/die) and III.2 with cholestyramine 6 g/die; these treatments resulted in a reduction of total cholesterol and LDL-C levels. After informed consent, a skin biopsy was obtained from II.4 for LDL binding studies.

Family 3: the proband (II.4) was a 37-year-old Caucasian Sicilian female (total cholesterol = 9.0 mmol/l), who reported two brothers (II.1 and II.3) and one sister (II.6) with hypercholesterolemia; the father (I.1) died of AMI at the age of 48 years. The 8-year-old daughter (III.2) also had hypercholesterolemia (9.7 mmol/l). Both the proband and her daughter did not have xanthelasmas or tendon xanthomas and ultrasound of carotid arteries did not document the presence of plaques. During the last year, II.4 has been treated with atorvastatin (10 mg/die) and III.2 with cholestyramine 6 g/die; these treatments resulted in a reduction of total cholesterol and LDL-C levels. After informed consent, a skin biopsy was obtained from II.4 for LDL binding studies.

Family 4: a 12-year-old Caucasian Sicilian boy (III.3) was referred to the Lipid Clinic for hypercholesterolemia (total cholesterol = 7.8 mmol/l). The 44-year-old father (II.3), who was tested afterwards, also showed high plasma total cholesterol levels (8.2 mmol/l); he had been smoking approximately 20 cigarettes/day for 20 years. On clinical examination, none of them were found to have xanthelasmas or tendon xanthomas. Ultrasound examination of the carotid arteries of subject II.3 revealed significant alterations of the arterial wall characterised by diffuse IMT increase and the presence of plaques (1.9 mm in the right bifurcation and 1.7 mm in the left one). II.3 also reported to have one brother (II.1), one sister (II.5) and one niece (III.6) with hypercholesterolemia and his father (I.1) died of myocardial infarction.

Family 5: a 54-year-old Caucasian Sicilian female (II.1) was referred to the Lipid Clinic for hypercholesterolemia (total cholesterol = 8.9 mmol/l). The proband's mother (I.2) was also hypercholesterolemic and suffered a myocardial infarction. One of the sons (III.1), 21 years old, was tested afterwards and showed high plasma total cholesterol levels (9.0 mmol/l). On clinical examination, none of them were found to have xanthelasmas or tendon xanthomas. Ultrasound examination of the carotid arteries of subject II.1 revealed significant alterations of the arterial wall, characterised by diffuse IMT increase and the presence of plaques (1.9 mm in the left bifurcation and 40% stenosis of the left internal carotid artery). The ultrasound of the carotid arteries of subject III.1 did not document any IMT alteration or plaques. Treatment with atorvastatin at 20 mg/die was begun.

Family 6: proband (III.1) was a 28-year-old Argentinian male patient of Paraguayan ancestry, who was referred to the Favaloro Foundation, Buenos Aires, with chest pain. Since the age of 4 years, she had had planar xanthomata, she was referred with a total serum cholesterol >25.8 mmol/l and, at the age of 21 years, had been diagnosed with aortic valve sclerosis. Upon physical examination, she had arcus corneale, extensive xanthomata and aortic insufficiency. Her lipid profile showed severe hypercholesterolemia (total cholesterol = 18.5 and LDL-C = 17.3 mmol/l), refractory to therapy with atorvastatin (80 mg/day) plus cholestyramine (12 g/day). Ultrasound examination showed stenosis of carotid arteries and a coronary angiography evidenced critical stenosis of coronary arteries. In August 2000, based on the clinical diagnosis of definite homozygous FH and the rapid progression of vascular disease, a living-donor liver transplantation was performed; her presumably half-sister (III.3) was accepted as a donor. The patient's lipid profile normalized immediately.

The proband's 7-year-old daughter (IV.1) had high total cholesterol levels (9.0 mmol/l). The proband reported also that her mother (II.2) had hypercholesterolemia, tendinous xanthomas and coronary artery disease; moreover, an uncle (II.5), with total cholesterol levels of approximately 11.7 mmol/l, had four of five children which showed severe hypercholesterolemia. Other family members were referred to have hypercholesterolemia (see the genealogical tree in Fig. 1).

The identity of the proband's father (II.1) was uncertain, but horizontal consanguinity was suspected. Among the family members, we were able to obtain DNA samples for molecular studies from the proband (III.1), her mother (II.2), her half-sister (III.3) and her daughter (IV.1).

Blood sampling, DNA isolation and biochemical analysis. Blood samples were collected from probands and available family members after an overnight fast. Blood was collected in a plain tube and in a ethylenediaminetetraacetic acid (EDTA) tube to separate serum and plasma, respectively. Plasma total cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides were measured enzymatically on a Mira Plus automatic analyser (Roche Diagnostics, Italy). LDL-cholesterol concentrations were calculated using the equation of Friedewald et al. (12). EDTA blood samples were also used for DNA isolation.

Polymerase chain reaction and direct sequencing of the LDL-R gene. To screen for small deletions, insertions or point mutations in the LDL-R gene, direct sequencing of PCR amplified genomic regions was performed. Briefly, genomic DNA was amplified using specific primers for each of the 18 exons encompassing the coding sequences and the splice site consensus at the intron/exon junctions of the LDL-R gene. Together with exon 1, 300 bp of the promoter region were analyzed. PCR fragments were purified using a commercial kit (Wizard PCR Prep DNA Purification System; Promega Italia, Italy) and sequenced directly in both directions using a Big-Dye Terminator cycle sequencing kit 1.1 (Applied Biosystems, Foster City, CA, USA); samples were then...
analysed on an ABI PRISM 310 automated DNA sequencing device (Applied Biosystems).

**Fibroblast cultures and isolation of mRNA.** Skin biopsies were taken from the proximal part of the volar side of the forearm. Fibroblasts were grown as monolayer in a 5% CO₂/air mixture, humidified at 37°C; the culture medium was Dulbecco’s modified Eagle’s medium (DMEM glutamax, Invitrogen, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 1% non-essential amino acids (Invitrogen). Cells, at their 3th passage, were harvested and mRNA was isolated using a standard procedure (RnaWiz, Ambion, UK) and resuspended in diethyl pyrocarbonate-treated water. The preparation was checked for integrity by agarose gel electrophoresis and quantitated by reading at 260 nm (BioPhotometer, Eppendorf, Germany).

**LDL binding assay.** Skin fibroblasts (HSFs) from the proband (II.4, family 3) and from a normal subject were cultured as described above. LDL labelled with the fluorescent dye dioctadecyl-indo-carbocyanine iodide (DIL; Sigma Aldrich, Italy) were prepared as described elsewhere (13). Approximately 75,000 human skin fibroblasts/well were seeded in 24-well plates (Corning Life Sciences, MA, USA) and grown to subconfluence. Forty-eight hours before the binding experiment, culture medium was replaced with 1 ml of DMEM supplemented with 10% lipoprotein depleted serum (LPDS), to overexpress cell LDL receptors. Monolayers were washed twice with PBS and incubated for 4 h with increasing amounts of DIL-LDL (from 0 to 120 μg/ml) alone or competed with a 50-fold excess of the same cold LDL fractions, in order to evaluate the non-specific fluorescence background. After three washes with cold PBS supplemented with 2 mM CaCl₂ plus 2 mM MgCl₂, cells were lysed in 0.1 N NaOH, 0.1% SDS at 37°C for 1 h. Aliquots were used for protein determinations (BCA micro; Pierce Biotechnology, Rockford, IL, USA) and cell incorporated fluorescence was read on an RXL10 Shimadzu fluorimeter (Shimadzu Corporation, Tokyo, Japan) at EX 535 nm and EM 570 nm. DIL-LDL incorporation was calibrated against a DIL-LDL scale in the same lysis buffer. Results were expressed as nanograms of incorporated

---

**Table I. Plasma lipid concentrations and clinical characteristics.**

<table>
<thead>
<tr>
<th>Subject</th>
<th>LDL-R Gene mutation</th>
<th>Age (years)</th>
<th>Sex</th>
<th>TC (mmol/l)</th>
<th>LDL-C (mmol/l)</th>
<th>HDL-C (mmol/l)</th>
<th>TG (mmol/l)</th>
<th>CVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III.1</td>
<td>g.1162delC</td>
<td>40</td>
<td>M</td>
<td>9.04</td>
<td>7.78</td>
<td>1.1</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Family 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.1</td>
<td>W</td>
<td>57</td>
<td>M</td>
<td>5.5</td>
<td>3.6</td>
<td>0.7</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>I.2</td>
<td>g.362G→A</td>
<td>54</td>
<td>F</td>
<td>5.7</td>
<td>4.3</td>
<td>0.9</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>II.1</td>
<td>g.362G→A</td>
<td>36</td>
<td>M</td>
<td>7.7</td>
<td>7.2</td>
<td>0.4</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>II.2</td>
<td>g.362G→A</td>
<td>33</td>
<td>M</td>
<td>7.5</td>
<td>6.4</td>
<td>0.7</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Family 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.4</td>
<td>g.2390-1G→A</td>
<td>37</td>
<td>F</td>
<td>9.0</td>
<td>7.5</td>
<td>1.4</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>II.5</td>
<td>W</td>
<td>42</td>
<td>M</td>
<td>5.3</td>
<td>3.8</td>
<td>1.2</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>III.1</td>
<td>W</td>
<td>5</td>
<td>M</td>
<td>4.2</td>
<td>3.7</td>
<td>0.6</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>III.2</td>
<td>g.2390-1G→A</td>
<td>8</td>
<td>F</td>
<td>9.7</td>
<td>8.5</td>
<td>0.8</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Family 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.2</td>
<td>W</td>
<td>43</td>
<td>F</td>
<td>5.8</td>
<td>3.4</td>
<td>2.0</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>II.3</td>
<td>g.1381G→T</td>
<td>46</td>
<td>M</td>
<td>8.2</td>
<td>6.8</td>
<td>1.0</td>
<td>1.9</td>
<td>CA</td>
</tr>
<tr>
<td>II.3</td>
<td>g.1381G→T</td>
<td>12</td>
<td>M</td>
<td>7.8</td>
<td>5.4</td>
<td>1.9</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Family 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.1</td>
<td>g.611G→A</td>
<td>54</td>
<td>F</td>
<td>8.9</td>
<td>6.8</td>
<td>1.0</td>
<td>2.3</td>
<td>CA</td>
</tr>
<tr>
<td>III.1</td>
<td>g.611G→A</td>
<td>21</td>
<td>M</td>
<td>9</td>
<td>7.6</td>
<td>0.8</td>
<td>1.3</td>
<td></td>
</tr>
<tr>
<td>Family 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.2</td>
<td>g.2051delC</td>
<td>49</td>
<td>F</td>
<td>9.3</td>
<td>7.5</td>
<td>1.1</td>
<td>1.6</td>
<td>CAD</td>
</tr>
<tr>
<td>II.5</td>
<td>W</td>
<td>26</td>
<td>F</td>
<td>5.2</td>
<td>3.0</td>
<td>1.1</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>II.3</td>
<td>g.2051delC</td>
<td>28</td>
<td>F</td>
<td>18.5</td>
<td>17.3</td>
<td>0.7</td>
<td>1.2</td>
<td>DA</td>
</tr>
<tr>
<td>IV.1</td>
<td>g.2051delC</td>
<td>7</td>
<td>F</td>
<td>9.0</td>
<td>7.6</td>
<td>1.1</td>
<td>1.6</td>
<td></td>
</tr>
</tbody>
</table>

TC, total cholesterol; TG, triglycerides; CVD, cardiovascular disease; CA, carotid atherosclerosis; CAD, coronary artery disease; DA, diffuse atherosclerosis; W, LDL-R gene wild-type. *Subject already treated with simvastatin 20 mg/die. "Presence of mutated allele in homozygosity. 
DIL-LDL/mg of cell proteins. All experiments were performed in triplicate.

Reverse transcription-polymerase chain reaction (RT-PCR) and cDNA sequencing. mRNA prepared from WT fibroblasts and white blood cells from the subject II.4 of family 3 were studied. One μg of total RNA was reverse transcribed using an antisense primer (20 pmol) localized in exon 18 of the LDL-R cDNA sequence at position 2643-2623 (5'-TCATCCTCCAGACTGACCATC-3'; GeneBank Accession no. BC014514) in a 20 μl total volume reaction mixture, containing 1.5 μl of 50 mM MgCl₂, 2 μl of 10X PCR buffer, 2 μl each of 10 mM dNTP, 0.5 μl of RNase inhibitor (Promega Italia). The mixture was incubated at 70˚C for 10 min, cooled down to 40˚C and 1 μl (10 U) of M-MLV reverse transcriptase (Promega Italia) was added. The reaction was carried out for 30 min and after denaturation at 95˚C for 5 min, the PCR reaction was settled. For the PCR reaction, the following ingredients were added to the above reaction mixture: 1.5 μl of MgCl₂ (50 mM), 8 μl of 10X PCR buffer, 68 μl of sterile water, 2 μl (20 pmol) of forward primer in exon 16 at position 2413-2431 (5'-ACGTTGCTGGCAGAGGAA-3'; GeneBank Accession no. BC014514), and 0.5 μl (2.5 U) of TaqDNA polymerase. Thirty cycles of PCR were performed using the following profile: 95˚C for 60 sec, 56˚C for 60 sec, and 72˚C for 60 sec, with a final elongation step at 72˚C for 7 min. PCR products were separated by electrophoresis on a 1.5% agarose gel and the different fragments were excised and purified using the Wizard PCR Preps DNA purification system (Promega Italia) for sequencing analysis.

Figure 2. Analysis of the LDL-R gene in families 1, 2 and 3. (A) Partial sequence of exon 8 in the proband of family 1. The nucleotide C deletion, shown by the arrow, causes a frameshift in one allele. (B) Partial sequence of exon 4 in a proband of family 2; the arrow indicates the G→A transition. On the right, the results of the screening for mutation, based on PCR amplification and Rsal enzymatic digestion of exon 4, is shown. (C) Sequence of the intron 16/exon 17 junction in the proband of family 3. On the right, AocII restriction map of the amplicon spanning the mutation site in the mutant allele. M, carrier of the mutant allele in heterozygosity; W, wild-type allele; L, 100-bp ladder.

Figure 3. Upper panel, schematic representation of the LDL-R gene encompassing exons 16 through 18 (up) and mRNA structure of the splicing variant when g.2390-1G→A is present. The mutated splice acceptor consensus and the normal and novel stop codons are indicated. Lower panel, reverse transcriptase-PCR analysis of LDL-R mRNA region coding for exons 16-18. RNA from normo-cholesterolemic generate an amplification product of 252 bp (lane 1), while RNA extracted from HSF of proband II.4, family 3, shows the wild amplicon and a longer product of approximately 300 bp (lane 2).

Results

Plasma lipid concentrations and clinical characteristics of the members of the six families studied are shown in Table I.

Family 1. The sequence of the LDL-R gene revealed a single nucleotide deletion in exon 8 g.1162delC (Fig. 2A) responsible for a frameshift with an expected premature stop codon (M391X).

Family 2. The sequence of the LDL-R gene revealed a G→A transition in exon 4 g.362G→A (Fig. 2B), responsible for a single amino-acid substitution in position 100 of LDL-R (C100Y). The mutation is present in heterozygosity in the four hypercholesterolemic subjects of this family. The mutation in the affected individuals creates a consensus sequence for the restriction endonuclease, Rsal. Consequently, a simple, reliable PCR-based screening technique could detect the G→A substitution at codon 100. This approach involved Rsal restriction digestion (Fermentas, Italy) of a 479-bp region of exon 4 spanning the mutated codon and subsequent analysis by 2% agarose gel electrophoresis (Fig. 2B).

Family 3. The direct sequence of amplified product including exon 17 and splice site sequences at the intron/exon junction...
revealed a G→A transition in the ultimate 3'-nucleotide of intron 16, g.2390-1G→A (Fig. 2C), thus, altering the 3'-splice acceptor AG dinucleotide to AA. As this mutation abolishes an AocII restriction site, a 382-bp PCR fragment encompassing the mutated site was digested with AocII (Fermentas, Italy) and the digestion products were separated on 2% agarose gel (Fig. 2C). This splicing mutation was further evaluated to investigate the effect on the processing of LDL receptor mRNA. RT-PCR analysis was performed with primers designed to selectively amplify the coding sequence spanning exons 16-18. As shown in Fig. 3, RNA from WT fibroblasts gives a single band of the expected size of 252 bp (lane 2), while RNA from proband’s fibroblasts (lane 1) shows two products, one corresponding to the wild-type messenger (252 bp) and a novel fragment of approximately 300 bp. Sequence analysis of this fragment revealed that the g.2390-1G→A substitution at the 3' acceptor splice site of intron 16 alters the consensus sequence for splicing and is responsible for retention of 62 nucleotides of intron 16 in the transcript, between exons 16 and 17 in the mutant mRNA (Fig. 3). Therefore, the predicted polypeptide will contain normally translated amino acids encoded by exon 16 which is followed by 21 new amino acids encoded by intron 16 and by out-of-frame amino acids encoded by exons 17 and 18; this insertion leads to a new stop codon (TAA) 210 nucleotides downstream of the TGA stop codon present in the normal sequence. The results of the LDL internalisation experiment are presented in Fig. 4. Human fibroblasts were cultured from skin biopsies obtained from the proband and a normal subject. HSFs were tested for their ability to bind and internalise increasing amounts of fluorescent LDLs. The data were modelled with the first order Michaelis-Menten equation; proband fibroblasts showed a reduced Vmax (87%) vs. control fibroblasts, while dissociation constants (kd) were similar (proband kd = 108% of control kd).

**Family 4.** The sequence of the LDL-R gene revealed a single nucleotide change in exon 10 g.1381G→T (Fig. 5A), responsible for an amino-acid change (G440C). The mutation abolished a restriction site for the restriction endonuclease, AcyI. By digestion of a 612-bp PCR fragment of exon 10 encompassing the mutated site with AcyI (Fermentas), followed by product separation on 2% agarose gel (Fig. 5A), it is possible to distinguish between carriers and normal individuals.

**Family 5.** The sequence of the LDL-R gene revealed a G→A transition in exon 4 g.611G→A (Fig. 5B), responsible for a single amino-acid substitution in position 183 of LDL-R (C183Y). The mutation is present in heterozygosity in the two hypercholesterolemic subjects. This mutation moves a restriction site for the restriction endonuclease, BstI (data not shown).

**Family 6.** The sequence of the LDL-R gene revealed a homozygous single nucleotide deletion in exon 14 g.2051delC (Fig. 5C), responsible for a frameshift with an expected premature stop codon (M687X). The direct sequence of exon 14 of the LDL-R gene of the proband’s mother and daughter
showed the presence of the g.2051delC mutation in heterozygosity, while the unaffected half-sister did not show the same mutation. A rapid test for the detection of the mutation was developed based on the creation of a Cac8I site in the mutated allele. Mutant and wild-type DNA can be distinguished by resolving the Cac8I digestion products of a 612-bp PCR fragment encompassing the mutated site on exon 14, on 2% agarose gel (Fig. 5C).

Discussion
In this report, we describe 5 novel mutations in the LDL-R gene that were associated with a phenotype of heterozygous familial hypercholesterolemic and 1 novel mutation detected in a homozygous FH patient.

We have analyzed the promoter region and the 18 exons and their flanking intron sequences of the LDL-R gene in each subject; the mutations described are the only sequence variations identified in the entire gene. Moreover, these nucleotide variations are expected to be the disease causing mutations because the co-segregation of the mutant allele with the phenotype of familial hypercholesterolemia has been demonstrated in all studied families.

Three missense mutations were found. Two of them (C100Y and C183Y) were in the ligand binding domain of LDL-R, one (G440C) was in the epidermal growth factor (EGF) precursor homology domain. Although expression of the mutant genes and functional studies of the encoded receptors have not been performed yet, we believe that the causative significance of these mutations is supported. The C100Y and the C183Y mutations concern two amino acids conserved among different animal species and neither of the three variants were found in 50 unrelated control subjects (100 chromosomes).

The two frameshift mutations identified (g.1162delC of exon 8 and g.2051delC in exon 14) result in the creation of premature stop codons at 25 and 24 codons downstream of the deletion sites, respectively, and these mutant alleles are predicted to code for truncated LDL-R proteins of 391 and 687 amino acids, respectively.

We found one novel mutation (g.2390-1G→A) at splicing acceptor consensus sequences located in intron 16 of the LDL-R gene. This base substitution changes the highly conserved dinucleotides AG in AA. Different mutations at this consensus sequence have been previously described (14,15). Analysis of the mutant mRNA showed the activation of a cryptic splice site in intron 16, causing the inclusion of 62 new nucleotides, spanning the 3′-end of intron 16 and the alteration of the correct reading frame, with a TAA stop codon 210 nucleotides downstream of the normal TGA stop codon in exon 18. The mutant LDL receptor protein will then present an elongation of 90 amino acids.

The mutation should affect two of the functional domains of the LDL receptor: the membrane spanning domain and the cytoplasmic domain. Binding studies showed a reduction in internalisation of LDL-DIL in cultured fibroblasts of the proband.

The g.2051delC in exon 14 was identified in a 28-year-old proband of Paraguayan ancestry who was first referred to the Favaloro Foundation, Buenos Aires, for coronary artery disease and clinical features of homozygous familial hypercholesterolemia. As far as we know, except for mutations in the LDL-R gene responsible for FH in Brazilian subjects (16,17), this is the first report of mutation in a patient from South America.

Traditionally, treatment options for homozygous familial hypercholesterolemia are considered apheresis and plasmapheresis (18), but liver transplantation has to be considered in selected cases of severe homozygous FH (19-21).

In our homozygous FH patient, a living-donor liver transplantation using a full right lobe was effective and lipid lowering drugs have not been required so far. Four years after liver transplantation, the patient is asymptomatic, gainfully employed, with normal liver and cardiac function.

In conclusion, we describe 6 novel mutations of the LDL-R gene responsible for familial hypercholesterolemia. The mutation identified in the South American patient represents the first description of a variant in South American patients other than Brazilian FH patients (16,17). The 5 mutations identified in the Sicilian patients demonstrate and confirm the heterogeneity of LDL-R gene mutation in Sicilian patients with a clinical diagnosis of FH.

Acknowledgements
This study was supported by University of Palermo, Italy; contract grant number: ‘60%’ to A.N., C.M.B. and M.R.A.

References